CTOs on the Move

Infinity Global

www.infinityrp.com

 
Infinity Global Inc. provides packaging solutions for luxury and specialty retailers. It offers boxes, such as rigid, folding, corrugated, and assortment boxes; paper bags, including machine made, handmade, merchandise, POP, and envelope paper bags; and poly bags, such as machine made bags, handmade bags, garment bags, and protective bags. The company also provides tissues, including solid, printed, fibered, crimped, and embossed tissues; and ribbons, such as solid, printed, and woven ribbons. In addition, it offers stickers/labels, garment covers/wraps, and hangers. The company sells its products through sales and distribution centers in the United States and internationally. Infinity Global Inc. was ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Stayable

Clean, spacious suites. Affordable prices. Flexible options. The reasons to stay are endless. Whether youre staying a night, the weekend, a month or longer, our suites are designed to provide all of the comforts of home.

Infillion

The world’s best brands rely on Infillion for advanced media solutions and technology to build their connected future across advertising, marketing, and CX.

G Technologies

G Technologies is a Buffalo, NY-based company in the Business Services sector.

SDV Logistics ( Canada)

SDV Logistics ( Canada) Inc. is a Saint-Laurent, QC-based company in the Business Services sector.

Alkeus Pharmaceuticals, Inc.

Alkeus Pharmaceuticals, Inc. is a late-stage biopharmaceutical company developing transformative therapeutics to address serious, progressive eye diseases that lead to blindness. Our lead compound, ALK-001, is an oral investigational drug being developed for the treatment of Stargardt disease (STGD) and Geographic Atrophy (GA) secondary to dry age-related macular degeneration. ALK-001 is a selectively-deuterated form of Vitamin A that slows the dimerization of Vitamin A, which is implicated in STGD, and has shown statistically-significant and clinically-meaningful efficacy in the TEASE-1 Phase 2 clinical trial. Based on these results, ALK-001 has been granted Breakthrough Therapy Designation for the treatment of Stargardt Disease.